Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. Read ...
The medtech giant hopes to bolster its position in the growing surgical robotics market, which is currently dominated by Intuitive Surgical.